CSF3 and acute myeloid leukemia: A phase Ib/II study by DiNardo et al. (2021) was conducted to assess combination therapy with fludarabine, cytarabine, G-CSF, idarubicin, and venetoclax (FLAG-IDA + VEN) in younger AML patients, with a median age of 44 years.